83948-38-3

Usage

Uses

Used in Synthetic Organic Chemistry:
1-(2-furyl)-1-phenylmethanamine is used as a building block for the preparation of various pharmaceuticals and other organic compounds. Its unique structure allows for the creation of a wide range of molecules with diverse properties and applications.
Used in Pharmaceutical Development:
Due to its potential biological activities, 1-(2-furyl)-1-phenylmethanamine is being studied for its role as a vasodilator and its ability to inhibit certain enzymes. This makes it a promising candidate for the development of new drugs targeting cardiovascular conditions and enzyme-related diseases.
Used in Research and Development:
1-(2-furyl)-1-phenylmethanamine is also utilized in research and development settings to explore its full potential and understand its effects on various biological systems. Further research is needed to fully comprehend its potential applications and implications in the field of medicine and pharmaceuticals.

InChI:InChI=1/C11H11NO/c12-11(10-7-4-8-13-10)9-5-2-1-3-6-9/h1-8,11H,12H2/p+1/t11-/m1/s1

Upstream product

• 98-01-1 furfural 
• 60907-91-7 2-furyl(phenyl)methanol 
• 235787-73-2 2-[azido(phenyl)methyl]furan 
• 83948-29-2 N-(2-furylmethylidene)-N-(1,1,1-trimethylsilyl)amine 

Downstream Products

• 135963-35-8 ([2]furyl-phenyl-methyl)-urea 
• 235787-75-4 6-hydroxy-2-phenyl-1-(4-tolylsulfonyl)-1,6-dihydro-2H-pyridin-3-one 
• 235787-78-7 6-phenyl-1-(4-tolylsulfonyl)-1,6-dihydropyridine-2,5-dione 
• 158471-23-9 N-(furan-2-yl(phenyl)methyl)-4-methylbenzenesulfonamide 

Relevant academic research and scientific papers

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

1,4-Reductive addition of hydrazoic acid to γ-oxo-α,β-unsaturated δ- lactones and -lactams: A convenient route to α-amino-γ-oxo-α,β- unsaturated δ-lactones and -lactams

γ-Oxo-α,β-unsaturated δ-lactones and lactams, which are easily accessible from their corresponding 2-furylcarbinols, were used as substrates for the 1,4-reductive addition of hydrazoic acid. The outcome of the reaction is the formation, in high yields, of

Preparation of Primary Amines and 2-Azetidinones via N-Trimethylsilyl Imines

Nonenolizable aldehydes react with lithium bis(trimethylsilyl)amide at ambient temperatures to afford solutions of N-trimethylsilyl aldimines.Treatment of these solutions with Grignard reagents or alkyllithiums followed by an aqueous workup gives primary amines in moderate to excellent yields.Treatment of N-trimethylsilyl aldimines with ester enolates provides an expedient route to 1-unsubstituted 2-azetidinones.

Hypoglycemic α cycloalkylphenylmethyl, furanalkyl, and thiophenealkyl lactamimides

A series of α cycloalkylphenylmethyl lactamimides and a series of furan and thiophenealkyl lactamimides were prepared for biological evaluation as an extension of earlier findings of hypoglycemic activity in lactamimides. Several compounds produced pronouced hypoglycemia after oral administration to fasted, glucose primed rats.